Pulsenmore Ltd (PULS) - Net Assets
Based on the latest financial reports, Pulsenmore Ltd (PULS) has net assets worth ILA74.51 Million ILA (≈ $199.75K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA120.34 Million ≈ $322.62K USD) and total liabilities (ILA45.83 Million ≈ $122.87K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PULS cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA74.51 Million |
| % of Total Assets | 61.92% |
| Annual Growth Rate | 91.59% |
| 5-Year Change | 3250.17% |
| 10-Year Change | N/A |
| Growth Volatility | 2092.13 |
Pulsenmore Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Pulsenmore Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Pulsenmore Ltd assets under control for the complete picture of this company's asset base.
Annual Net Assets for Pulsenmore Ltd (2019–2024)
The table below shows the annual net assets of Pulsenmore Ltd from 2019 to 2024. For live valuation and market cap data, see Pulsenmore Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA96.89 Million ≈ $259.75K |
-26.73% |
| 2023-12-31 | ILA132.23 Million ≈ $354.51K |
-29.48% |
| 2022-12-31 | ILA187.52 Million ≈ $502.73K |
+21.98% |
| 2021-12-31 | ILA153.73 Million ≈ $412.16K |
+5215.84% |
| 2020-12-31 | ILA2.89 Million ≈ $7.75K |
-22.84% |
| 2019-12-31 | ILA3.75 Million ≈ $10.05K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Pulsenmore Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15678400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA2.00K | 0.00% |
| Other Comprehensive Income | ILA10.97 Million | 11.32% |
| Other Components | ILA253.21 Million | 261.34% |
| Total Equity | ILA96.89 Million | 100.00% |
Pulsenmore Ltd Competitors by Market Cap
The table below lists competitors of Pulsenmore Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shradha Infraprojects Limited
NSE:SHRADHA
|
$22.89 Million |
|
Yung Zip Chemical Ind Co Ltd
TWO:4102
|
$22.90 Million |
|
TherapeuticsMD Inc
NASDAQ:TXMD
|
$22.92 Million |
|
Gumho NT Co Ltd
KQ:130500
|
$22.92 Million |
|
Indofarma Tbk
JK:INAF
|
$22.88 Million |
|
Music Broadcast Limited
NSE:RADIOCITY
|
$22.88 Million |
|
Mistral Iberia Real Estate SOCIMI S.A.
MC:YMIB
|
$22.87 Million |
|
Resverlogix Corp.
TO:RVX
|
$22.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pulsenmore Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 132,232,000 to 96,887,000, a change of -35,345,000 (-26.7%).
- Net loss of 36,736,000 reduced equity.
- New share issuances of 3,000 increased equity.
- Other comprehensive income increased equity by 659,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-36.74 Million | -37.92% |
| Share Issuances | ILA3.00K | +0.0% |
| Other Comprehensive Income | ILA659.00K | +0.68% |
| Other Changes | ILA729.00K | +0.75% |
| Total Change | ILA- | -26.73% |
Book Value vs Market Value Analysis
This analysis compares Pulsenmore Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 86.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2006.54x to 86.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ILA0.65 | ILA1313.00 | x |
| 2020-12-31 | ILA0.50 | ILA1313.00 | x |
| 2021-12-31 | ILA29.76 | ILA1313.00 | x |
| 2022-12-31 | ILA31.20 | ILA1313.00 | x |
| 2023-12-31 | ILA20.65 | ILA1313.00 | x |
| 2024-12-31 | ILA15.12 | ILA1313.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pulsenmore Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -380.25%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.46x
- Recent ROE (-37.92%) is above the historical average (-119.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -126.31% | 0.00% | 0.00x | 1.60x | ILA-5.11 Million |
| 2020 | -481.92% | 0.00% | 0.00x | 3.12x | ILA-14.23 Million |
| 2021 | -16.67% | -1623.89% | 0.01x | 1.09x | ILA-41.00 Million |
| 2022 | -11.80% | -204.54% | 0.05x | 1.26x | ILA-40.87 Million |
| 2023 | -44.29% | -946.46% | 0.03x | 1.36x | ILA-71.79 Million |
| 2024 | -37.92% | -380.25% | 0.07x | 1.46x | ILA-46.42 Million |
Industry Comparison
This section compares Pulsenmore Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $99,748,111
- Average return on equity (ROE) among peers: -40.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pulsenmore Ltd (PULS) | ILA74.51 Million | -126.31% | 0.62x | $22.89 Million |
| Allmed Solutions Ltd (ALMD) | $30.22 Million | -165.46% | 0.44x | $8.53 Million |
| Erika Carmel Ltd (BCUR) | $88.06 Million | -24.76% | 0.42x | $4.69 Million |
| Bio-View Ltd (BIOV) | $18.18 Million | 11.59% | 0.71x | $4.83 Million |
| Brainsway Ltd (BWAY) | $57.32 Million | -11.27% | 0.32x | $463.07 Million |
| Erech Finance Cahalacha Ltd (EFNC) | $28.37 Million | -88.27% | 1.44x | $1.74 Million |
| Epitomee Medical Ltd (EPIT) | $39.45 Million | -39.02% | 0.40x | $62.09 Million |
| Erika Carmel-Tech Ltd (ERKA) | $88.06 Million | -24.76% | 0.42x | $5.82 Million |
| Human Xtensions Ltd (HUMX) | $104.53 Million | -51.30% | 0.15x | $2.12 Million |
| Ilex Medical (ILX) | $443.54 Million | 27.20% | 0.76x | $141.31 Million |
About Pulsenmore Ltd
Pulsenmore Ltd. engages in the provision of self-scan ultrasound devices for remote clinical diagnosis and screening in Israel and Europe. The company offers Pulsenmore home ultrasound system, a handheld ultrasound cradle dock with the patient's smartphone; mobile app for uploading images to the cloud for review; and clinician dashboard for clinician to review a stored video or guide a scan in re… Read more